ffpe tissue—pyrosequencing Search Results


ffpe tissue—pyrosequencing  (Pyrosequencing Inc)
90
Pyrosequencing Inc ffpe tissue—pyrosequencing
Clinicopathological presentations of LCH patients
Ffpe Tissue—Pyrosequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ffpe tissue—pyrosequencing/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
ffpe tissue—pyrosequencing - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Clinicopathological presentations of LCH patients

Journal: Orphanet Journal of Rare Diseases

Article Title: Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing

doi: 10.1186/s13023-021-01912-3

Figure Lengend Snippet: Clinicopathological presentations of LCH patients

Article Snippet: Heritier [ ] , French , 173/315 (55%) , 173/315 (55%) , 3.2 years, 0–17.9 years , 167:148, 1.13 , FFPE tissue—Pyrosequencing or AS-qPCR or ddPCR or IHC , Age, gender, stage, involvement, follow-up years, 5-year relapse, death, permanent consequence, therapy , Median follow-up years, skin, risk organ, second-line therapy and/or rescue therapy requirement.

Techniques: Mutagenesis

Summary of published cohorts of LCH patients bearing BRAF V600E mutations in tissue

Journal: Orphanet Journal of Rare Diseases

Article Title: Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing

doi: 10.1186/s13023-021-01912-3

Figure Lengend Snippet: Summary of published cohorts of LCH patients bearing BRAF V600E mutations in tissue

Article Snippet: Heritier [ ] , French , 173/315 (55%) , 173/315 (55%) , 3.2 years, 0–17.9 years , 167:148, 1.13 , FFPE tissue—Pyrosequencing or AS-qPCR or ddPCR or IHC , Age, gender, stage, involvement, follow-up years, 5-year relapse, death, permanent consequence, therapy , Median follow-up years, skin, risk organ, second-line therapy and/or rescue therapy requirement.

Techniques: Mutagenesis, Sequencing, Biomarker Discovery, Activation Assay, Expressing